mCureX, a subsidiary of RNAi therapeutic developer, OliX Pharmaceuticals, has signed memorandums of understanding with Samyang Holdings to advance development of a messenger ribonucleic acid (mRNA) vaccine for COVID-19 and with GC Pharma to develop mRNA vaccines and therapeutics for respiratory infections and other diseases more broadly.
Under the agreement with Samyang Holdings, the companies will develop an mRNA vaccine for COVID-19, leveraging Samyang’s drug delivery system (DDS) which is designed to protect nucleic acids, like mRNA, that are susceptible to degradation by certain enzymes in the human body.
The DDS is based on proprietary bioabsorbable polymer technology that enables therapeutics to be safely and effectively delivered into the human body. mCureX, in close collaboration with Samyang Holdings, is developing a COVID-19 vaccine that will effectively target viral variants.
In collaboration with GC Pharma, mCureX will research and develop mRNA vaccines and treatments for respiratory infections and other diseases based on its proprietary mRNA technology, while GC Pharma will provide clinical development and manufacturing expertise and support.
“Vaccines and therapeutics based on mRNA hold great promise in preventing and treating human diseases given their relatively short development timelines,” said Sun Woo Hong, CEO of mCureX.
“Our collaborations with Samyang Holdings and GC Pharma will enable us to rapidly develop mRNA vaccines and therapeutics to fulfill urgent and unmet medical needs in Korea and beyond.”